Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study
Abstract Background Brain metastases (BMs) are almost a norm and devastating complication of metastatic breast cancer (MBC), but patients with active BMs (untreated or progressing to prior local therapy) are usually excluded from participating in clinical trials. Trastuzumab deruxtecan (T-DXd) has s...
Saved in:
| Main Authors: | Fangfang Duan, Xin Hua, Wei Lu, Xingxing Gui, Jingdun Xie, Xudong Wang, Yuyu Ma, Wenyu Zhai, Wen Xia |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Breast Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13058-025-02088-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
by: Jinmei Zhou, et al.
Published: (2025-05-01) -
Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01) -
Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01) -
Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis
by: George W. Jr. Sledge, et al.
Published: (2025-08-01) -
Concordance of HER2-low scoring in breast carcinomas among pathologists
by: Snježana Tomić, et al.
Published: (2025-07-01)